<DOC>
	<DOCNO>NCT03071081</DOCNO>
	<brief_summary>This study evaluate safety tolerability TOP1288 oral single ascend multiple dos healthy subject .</brief_summary>
	<brief_title>Study Safety Tolerability TOP1288 Administered Orally Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<criteria>1 . Subject healthy male , age 18 55 year age ( inclusive ) Screening . 2 . Subject body mass index ( BMI ) 18.0 29.9 kg/m2 ( inclusive ) , body weight least 50 kg Screening . 3 . Subject good physical mental health opinion Investigator . 4 . Subject clinical laboratory test result within reference range test laboratory unless result outside reference range deem clinically significant Investigator Screening Day 1 . 5 . Subject supine blood pressure pulse rate within normal range 5 minute ' rest ( systolic blood pressure : 90 140 mmHg , diastolic blood pressure : 40 90 mmHg , pulse rate : 40 90 beat per minute ) Screening Day 1 . 6 . Subjects must willing comply contraception restriction protocol study . 7 . Subject regular bowel open usually 1 motion per day normal consistency . 1 . Subject participate another study investigational medication ( medical device ) within last 3 month 5 halflives investigational medication , whichever longer , prior first day dose . 2 . Subject make blood donation ( &gt; 400 mL ) comparable blood loss ( &gt; 350 mL ) within last 3 month prior first administration study drug . 3 . Subject test positive human immunodeficiency virus ( HIV ) 1/2 antibody , hepatitis B surface antigen , hepatitis C antibodies Screening . 4 . Subject history alcohol and/or drug abuse . 5 . Subject alcohol consumption 21 unit alcohol per week . 6 . Subject test positive alcohol and/or drug ( urine test ) Screening admission . 7 . Subject receive prescription nonprescription medication , include overthecounter medication , nutraceuticals ( e.g. , St. John 's Wort , ginseng , kava kava , Ginkgo biloba melatonin ) , food beverage contain grapefruit vitamin supplement within 14 day prior admission ( Day 1 ) nutraceuticals contain caffeine xanthinerelated substance within 72 hour prior admission ( Day 1 ) . Foods beverages contain Sevilletype ( sour ) orange , poppy seed also exclude within time period . 8 . The subject history daily consumption 5 cup coffee tea . 9 . Subject know hypersensitivity component study drug . 10 . Subject history clinically significant acute chronic condition affect colon and/or rectum and/or anus , include haemorrhoid irritable bowel syndrome , sufficient cause symptom and/or judgement PI Sponsor 's study Physician/Medical Monitor would interfere subject 's participation study . 11 . Any finding predose endoscopy PI 's judgement would interfere subject participation study . 12 . Subject acute chronic condition affect GI motility constipation diarrhoea would , judgement PI Sponsor 's study Physician/Medical Monitor , interfere subject 's participation study 13 . Subject cardiovascular cerebrovascular disease , include hypertension , angina , ischaemic heart disease , transient ischaemic attack , stroke peripheral arterial disease sufficient cause symptom and/or require therapy maintain stable status . 14 . Subject active infection ( e.g. , sepsis , pneumonia , abscess ) serious infection ( result hospitalisation require parenteral antibiotic treatment ) within 6 week prior study drug administration . 15 . Subject history positive tuberculosis test evidence possible tuberculosis latent tuberculosis infection Screening ( interferon gamma release assay test ) attribute prior Bacillus CalmetteGuérin inoculation . 16 . Subject receive live attenuate vaccination within 6 week prior Screening intend vaccination course study . 17 . Subject follow haematology value Screening Day 1 : Haemoglobin , &lt; 13 g/dL . Absolute neutrophil count &lt; 1.5 x 109/L ( &lt; 1500/μL ) . 18 . Subject 12lead electrocardiogram ( ECG ) result consider potentially clinically significant , e.g. , QTcF &gt; 450 m , bundle branch block , evidence myocardial ischaemia , Screening Day 1 . 19 . Subject abnormality ECG , opinion Investigator , increase risk associate participate study . 20 . Subject renal liver impairment Screening Day 1 , define : Serum creatinine level ≥ 135 μmol/L , Alanine aminotransferase ( ALT ) and/or aspartate aminotransferase ( AST ) ≥2 x upper limit normal , Alkaline phosphate and/or bilirubin &gt; 1.5 x upper limit normal ( isolated bilirubin 1.5 x upper limit normal acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 21 . Subject active neoplastic disease history neoplastic disease within 5 year Screening ( except basal squamous cell carcinoma skin carcinoma situ definitively treat standard care ) . 22 . Subject acute chronic illness , opinion Investigator Sponsor 's study Physician/Medical Monitor , could pose threat harm subject 's participation study . 23 . The subject use nicotinecontaining product ( include , limited , cigarette , pipe , cigar , chew tobacco , nicotine patch , nicotine gum ) within 2 week prior admission study centre ( Day 1 ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>